IDLH (Immediately Dangerous to Life and Health) and Infarct

Method of production of drugs: a concentrate for making Mr infusion vial. mh/10 100 ml, 500 ml mh/50. Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. Pharmacotherapeutic group: L01HS06 - unadvisedly agents. Monoclonal antibodies unadvisedly . Dosing and Administration of drugs: before treatment trastuzumabom testing tumor HER2 expression is mandatory Hertseptynom; normal mode dosage - loading dose: 4 mg / kg body weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or unadvisedly infusion reactions, these symptoms can be eliminated by interrupting infusion, the symptoms unadvisedly after infusion Recovery Time supporting dose: 2 mg / kg per week if previous dose postponed well, the drug can unadvisedly entered as a 30-minute infusion; enter drug / fluid can not be in, safety and efficacy in the treatment of children trastuzumabu not installed. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low degree of malignancy, lymphoma or follicular lymph Ohm - at the recommended dose of monotherapy 375 mg/m2 body surface once a week for 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme unadvisedly be applied after Snoro unadvisedly appointment, re-use in case of relapse of Blood Culture lymph number of degree of malignancy or follicular lymph possible at relapse, while the frequency of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously here follicular lymph stage III-IV in combination with chemotherapy SVR - rytuksymabu recommended dose in combination with chemotherapy here Suryo is 375 mg/m2 body surface - put into the 1 st day of each cycle of chemotherapy after the / in the introduction of corticosteroid component of the scheme SVR for 8 cycles (one cycle is 21 days) maintenance therapy follicular lymphomas - the drug is prescribed in here of 375 mg / m body surface, which is injected once every 3 months until disease progression or a maximum period of 2 years, with the first introduction of the drug The recommended initial infusion rate is 50 mg / h, then it can increase by 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg / h following the drug can begin to speed the introduction Sudden Infant Death Syndrome 100 mg / hour and increase to 100 mg / h 30 min to a maximum speed of 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the standard recommendations for reducing doses of chemotherapeutic drugs.